Therapeutic Workshop
Come up for Air! What's in the Pipeline for Cystic Fibrosis?
Friday, October 31, 2008
9:45am - 11:00am
Presidio
With only two approved treatments for cystic fibrosis, no cure and no drug approved since 1997, companies (both public and private) have been jumping on the CF bandwagon. Treatments thus far have remained focused on managing the symptoms of CF and include mucolytics, anti-inflammatory drugs, antibiotics, enzyme therapies and others. With a better understanding of the genetic defect that characterizes CF and the biology of the cystic fibrosis airway, therapy is moving to a pre-symptomatic approach that targets the underlying causes of the disease. This panel will focus on the current phase 2 and 3 pipeline that may soon yield important new therapies for CF.
Moderator
- Liana Moussatos, PhD, Senior Healthcare Research Analyst, Pacific Growth Equities
Panelists
Industry:
- Amy E. Schaberg, RN, BSN, Vice President, Clinical Research, Inspire Pharmaceuticals
- Temitayo Ajayi, MD, Director of Clinical Development, PTC Therapeutics
Clinician:
- Richard Moss, MD, Professor of Pediatrics, Director of Cystic Fibrosis Center, Chief of the Division of Allergy - Immunology, Stanford University
- L. Terry Spencer, MD, Director of Cystic Fibrosis Center, Director of Clinical Research, Division of Respiratory Diseases, Children's Hospital Boston
Who's Who
Liana Moussatos, PhD Liana Moussatos joined Pacific Growth Equities from UBS Global Asset Management where she was director and portfolio manager of the UBS Global Biotech Funds for five years. Previously, Liana was with Bristol-Meyers Squibb where she was a manager in University and Government Licensing, External Science and Technology. Liana has also worked with Sloan-Kettering Cancer Institute in the office of Industrial Affairs and the National Cancer Institute in the Office of Technology Development. Liana received her BS in Entomology and her MS in Zoology and Biochemistry from Clemson University, her Ph.D. in Plant Pathology from the University of California, Davis and completed a postdoctoral research fellowship in cellular and molecular Physiology at the Yale School of Medicine.
Amy E. Schaberg, RN, BSN Ms. Schaberg joined Inspire in August 2001 as Senior Director, Clinical Research. She worked with Inspire as a consultant for two years prior to accepting this position. Ms. Schaberg was promoted to Vice President, Clinical Research in April 2003. She is responsible for directing the scientific and operational aspects of clinical activities for clinical development programs in the pulmonary therapeutic area. She brings to Inspire over 22 years of clinical development experience including the design and implementation of clinical trials and the reporting of clinical trial data, including the clinical portions of two New Drug Applications (NDAs) and two supplemental NDAs. Prior to consulting for Inspire, Ms. Schaberg was employed for ten years at Glaxo Wellcome in various capacities in clinical research. She holds a B.S. in Nursing from Boston University.
Temitayo Ajayi, MD Dr. Ajayi joined PTC Therapeutics as Director of Clinical Development in July 2008. She was an Associate Director of Clinical Research in the Allergy, Respiratory, and Clinical Immunology division at Schering-Plough Corporation from 2006 to 2008. Prior to entering the pharmaceutical industry, she was trained in Pulmonary and Critical Care Medicine at the University of California, San Francisco where she conducted basic and clinical research with P. aeruginosa and severe pneumonia and was Clinical Instructor from 2003 to 2006. Dr. Ajayi was trained in Internal Medicine at Columbia Presbyterian Medical Center in New York City, received her medical degree from Albert Einstein College of Medicine in New York City, and her undergraduate degree in Biochemistry from Harvard University in Cambridge, MA. She is the American Board of Internal Medicine-certified in Internal Medicine and Pulmonary Diseases.
Richard Moss, MD Dr. Moss is Professor of Pediatrics, Director of the Cystic Fibrosis Center and Chief, Division of Allergy-Immunology at Stanford University. He also directs the Ross Mosier Laboratory for Cystic Fibrosis Research at the Lucile Packard Children's Hospital at Stanford. He has spent over 25 years treating and conducting research in patients with cystic fibrosis having published widely on this topic in peer-reviewed journals.
L. Terry Spencer, MD Dr. Spencer is the Director of the Cystic Fibrosis Center and the Director of Clinical Research, Division of Respiratory Diseases at Children's Hospital Boston. He also has an appointment as Assistant Professor of Pediatrics, Harvard Medical School. Previously, he was Clinical Associate Professor of Pediatrics, Director of the Cystic Fibrosis Care Center, and Division Chief of Pediatric Pulmonary Diseases at University of Florida College of Medicine. Dr. Spencer is an active investigator of new agents for patients with cystic fibrosis and has been involved in numerous clinical trials.